

					
						November 16, 2017 - By Darrin Black
The stock of Novo Nordisk A S (ADR) (NYSE:NVO) is a huge mover today! About 270,896 shares traded. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since November 16, 2016 and is downtrending. It has underperformed by 40.63% the S&P500.The move comes after 7 months positive chart setup for the $99.11B company. It was reported on Nov, 16 by Barchart.com. We have $54.51 PT which if reached, will make NYSE:NVO worth $7.93B more.Electromed, Inc. develops, manufactures and markets airway clearance products, which apply High Frequency Chest Wall Oscillation therapy in pulmonary care for patients of all ages. The company has market cap of $46.59 million. The Company’s products include the SmartVest Airway Clearance System (SmartVest System), the SmartVest SQL System and others. It has a 22.14 P/E ratio. As of June 30, 2016, the SmartVest System is available in two models: SV2100 and SQL.Novo Nordisk A/S is a global healthcare firm engaged in diabetes care. The company has market cap of $99.11 billion. The Firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a 20.58 P/E ratio. The Firm operates through two business divisions: diabetes and obesity care, and biopharmaceuticals.Among 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Novo Nordisk (ADR) had 15 analyst reports since August 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by UBS on Tuesday, December 6. On Monday, October 31 the stock rating was downgraded by DNB Markets to “Hold”. The company was upgraded on Friday, August 28 by Zacks. The company was upgraded on Tuesday, September 13 by BNP Paribas. On Monday, October 31 the stock rating was downgraded by Citigroup to “Neutral”. The firm earned “Neutral” rating on Friday, September 23 by Piper Jaffray. The company was upgraded on Monday, October 19 by Jyske Bank. The firm earned “Market Perform” rating on Friday, August 28 by Leerink Swann. On Friday, October 28 the stock rating was downgraded by Bank of America to “Underperform”. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) has “Sell” rating given on Monday, February 8 by UBS.Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on February, 1. They expect $0.56 earnings per share, up 12.00% or $0.06 from last year’s $0.5 per share. NVO’s profit will be $1.10B for 22.53 P/E if the $0.56 EPS becomes a reality. After $0.62 actual earnings per share reported by Novo Nordisk A S (ADR) for the previous quarter, Wall Street now forecasts -9.68% negative EPS growth. Thompson Davis & Co. Inc. holds 0.12% of its portfolio in Electromed, Inc. for 13,800 shares. Teton Advisors Inc. owns 106,654 shares or 0.06% of their US portfolio. Moreover, Globeflex Capital L P has 0.04% invested in the company for 31,475 shares. The Texas-based Bridgeway Capital Management Inc has invested 0.02% in the stock. Carlson Capital Management, a Minnesota-based fund reported 14,134 shares. About 8,615 shares traded. Electromed, Inc. (ELMD) has risen 9.44% since November 16, 2016 and is uptrending. It has underperformed by 7.26% the S&P500.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.By1 Darrin Black



(adsbygoogle = window.adsbygoogle || []).push({});
